FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 12
Grant agreement number
806776

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
5 499 882
EFPIA in kind
6 927 335
Total Cost
12 427 218

Summary

As people age, their immune systems become weaker, and they become more vulnerable to infectious diseases. Preventing these infections through a proper vaccination strategy is essential for promoting healthy ageing. The VITAL project will map the burden of vaccine-preventable infectious diseases in the elderly, and investigate vaccinations and immunity to infections in the ageing population. The team will also calculate the clinical and economic consequences of possible vaccination strategies in different age and risk groups, and develop educational materials for stakeholders such as healthcare providers. Ultimately, by addressing the challenge of infectious diseases in the elderly, the VITAL project will contribute to better health for the ageing populations, and a reduced burden on healthcare systems.

Participants Show participants on map

EFPIA companies
  • Biomerieux SA, Marcy L'Etoile, France
  • Federation Europeenne D'Associations Et D'Industries Pharmaceutiques, Brussels, Belgium
  • Glaxosmithkline Biologicals SA, Rixensart, Belgium
  • Janssen Vaccines & Prevention BV, Leiden, Netherlands
  • Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi Pasteur SA, Lyon, France
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Centre National De La Recherche Scientifique Cnrs, Paris, France
  • Folkehelseinstituttet, Oslo, Norway
  • Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Istituto Superiore Di Sanita, Roma, Italy
  • Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
  • Statens Serum Institut, Copenhagen S, Denmark
  • Universita Degli Studi Di Ferrara, Ferrara, Italy
  • Universitaet Innsbruck, Innsbruck, Austria
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universite Jean Monnet Saint-Etienne, Saint Etienne Cedex 2, France
  • University College London, London, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Mihajlovic Jovan, Novi Sad, Serbia
  • P95 CVBA, Leuven, Belgium
  • Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag, Budapest, Hungary

CONTACT

Project coordinator
Debbie VAN BAARLE
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
debbie.van.baarle[at]rivm.nl